What is the clinical evidence from this study?

Study design: Cohort. Population: Chronic Chagas cardiomyopathy (n=1959). Intervention: Chronic Chagas cardiomyopathy. Primary outcome: Death (planned primary outcome for the 2-year follow-up).

May 1, 2016BMJ OpenOpen Access

Longitudinal study of patients with chronic Chagas cardiomyopathy in Brazil (SaMi-Trop project): a cohort profile

View Full Paper

Ask AI

Bookmark

Key result

In a baseline profile of 1,959 patients with chronic Chagas cardiomyopathy, 46% had functional class >II and 30% had NT-ProBNP levels >300 pg/mL, highlighting significant residual morbidity and undertreatment in remote areas.

Population

1959 patients with chronic Chagas cardiomyopathy, mostly female, aged 50-74 years, from 21 municipalities in…

Design

Cohort

Follow-up

2 years

Authors

CCClareci Silva Cardoso ÉSÉster Cerdeira Sabino COCláudia Di Lorenzo Oliveira

Discussion

Member takes

Overview

Undertreatment persists in remote Chagas cardiomyopathy; leaves open optimal management strategies pending prospective trials.

Study Design

Type

Cohort (n=1,959)

Multicenter

Yes

Structured PICO

Population

1,959 patients aged 19 years or older with chronic Chagas cardiomyopathy and specific ECG abnormalities from 21 municipalities in Brazil, enrolled for a 2-year follow-up to evaluate clinical prediction rules.

Outcome

Evaluation of a clinical prediction rule based on ECG, brain natriuretic peptide (BNP) levels, and other biomarkers

The SaMi-Trop cohort establishes a large prospective registry of chronic Chagas cardiomyopathy in Brazil, highlighting significant residual morbidity and identifying NT-proBNP as a key marker of disease severity.

Limitations

Lack of baseline echocardiograms, which could help in the clinical stratification of patients
No data on weight and height in the health services indicators were included at the baseline
No indeterminate form or negative controls were included in this cohort

Cite This Study

Cardoso et al. (2016) conducted a cohort in Chronic Chagas cardiomyopathy (n=1,959). Chronic Chagas cardiomyopathy was evaluated on Death (planned primary outcome for the 2-year follow-up). In a baseline profile of 1,959 patients with chronic Chagas cardiomyopathy, 46% had functional class >II and 30% had NT-ProBNP levels >300 pg/mL, highlighting significant residual morbidity and undertreatment in remote areas.

synapsesocial.com/papers/6a92e4f82f178fb23ebb64e4 https://doi.org/10.1136/bmjopen-2016-011181

View Full Paper

Ask AI

Bookmark

May 1, 2016BMJ OpenOpen Access

Longitudinal study of patients with chronic Chagas cardiomyopathy in Brazil (SaMi-Trop project): a cohort profile

View Full Paper

Ask AI

Bookmark

Key result

Population

1959 patients with chronic Chagas cardiomyopathy, mostly female, aged 50-74 years, from 21 municipalities in…

Design

Cohort

Follow-up

2 years

Authors

CCClareci Silva Cardoso ÉSÉster Cerdeira Sabino COCláudia Di Lorenzo Oliveira

Discussion

Member takes

Overview

Undertreatment persists in remote Chagas cardiomyopathy; leaves open optimal management strategies pending prospective trials.

Study Design

Type

Cohort (n=1,959)

Multicenter

Yes

Structured PICO

Population

Outcome

Evaluation of a clinical prediction rule based on ECG, brain natriuretic peptide (BNP) levels, and other biomarkers

Limitations

Lack of baseline echocardiograms, which could help in the clinical stratification of patients
No data on weight and height in the health services indicators were included at the baseline
No indeterminate form or negative controls were included in this cohort

Cite This Study

synapsesocial.com/papers/6a92e4f82f178fb23ebb64e4 https://doi.org/10.1136/bmjopen-2016-011181

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark